Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2009. The report serves as an update on the company's progress regarding government orders for its pandemic (H1N1) 2009 adjuvanted vaccine.
Key Financial Metrics
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity for the reporting period. The only financial figure disclosed relates to specific government contracts:
- US Government Agreements: Agreements in place to supply pandemic products worth $250 million (confirmed as of August 4, 2009).
Material Changes and Operational Updates
Since August 4, 2009, GSK has secured 22 new government orders for an additional 149 million doses of the pandemic vaccine. This brings the total number of doses ordered to 440 million. The company confirmed that first supplies are scheduled to ship during the week commencing October 5, 2009, with deliveries extending through the fourth quarter of 2009 and the first half of 2010.
Outlook, Risks, and Contingencies
Future deliveries are contingent upon several factors, including government import/export regulations, regulatory approvals, approvals for outsourced packaging and filling, and testing required by reference laboratories. GSK cautions that forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections, referencing the "Risk Factors" section of its 2008 Annual Report on Form 20-F.
Key Facts for Investor Verification
- Total pandemic (H1N1) vaccine doses ordered: 440 million.
- Value of US Government pandemic product agreements: $250 million.
- First shipment date: Week commencing October 5, 2009.
- Delivery timeline: Q4 2009 and H1 2010.
- Delivery contingencies: Regulatory approvals, export/import regulations, and packaging/filling approvals.